The present invention relates to new camptothecin derivatives of formula (I) wherein B is a group B' or B'' wherein each of (x) and (y) is a single or double bond, R₁ and R₂ are each independently hydrogen, C₁-C₅ alkyl, C₅-C₇ cycloalkyl, phenyl C₁-C₆ alkyl or an unsubstituted or substituted phenyl ring, R₃ and R₄ are (a) each independently substituents having the same meaning of R₁ and R₂ or (b) combined together with the nitrogen atom to which they are linked to form a 3-7 membered saturated, unsubstituted or substituted heterocyclic ring, which may additionally contain another heteroatom selected from nitrogen, oxygen and sulphur, and A is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid, provided that (i) when (x) is a double bond, (y) is a single bond and when (y) is a double bond, (x) is a single bond, and (ii) when B is a group B', then one of R₃, R₄ and R₄ is absent; R₆ is hydrogen or C₁-C₅ alkyl, X is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₅-C₇ cycloalkyl, C₅-C₇ cycloalkoxy, benzoyloxy, amino, hydroxy, nitro, a halogen atom or a methyleneolxy group linked to the position 10 and 11 of the molecule; and the pharmaceutically acceptable salts thereof. The camptothecin derivatives according to the invention are useful in therapy as antitumor agents.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>GE</td>
<td>Georgia</td>
</tr>
<tr>
<td>GN</td>
<td>Guinea</td>
</tr>
<tr>
<td>GR</td>
<td>Greece</td>
</tr>
<tr>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>IE</td>
<td>Ireland</td>
</tr>
<tr>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>KE</td>
<td>Kenya</td>
</tr>
<tr>
<td>KG</td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
</tr>
<tr>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>KZ</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>VN</td>
<td>Viet Nam</td>
</tr>
</tbody>
</table>
The present invention relates to new camptothecin derivatives, to a process for their preparation, and to pharmaceutical compositions containing them.

Background of the invention

Camptothecin and some of its analogous compounds such as, for example, 9-amino camptothecin, display potent antitumor activity by the inhibition of Topoisomerase I which is a monomeric enzyme involved in some important cellular functions and cellular growth (see, for instance, Wani et al., J. Med. Chem. 1987, 30, 1774; Hsiang et al., Cancer Res. 1989, 49, 4385 and Cancer Res. 1989, 49, 1465).

Unfortunately, camptothecin and some of its derivatives such as the above mentioned 9-amino camptothecin, suffer of low solubility in aqueous solutions. This drawback makes very difficult their administration and the preparation of acceptable pharmaceutical formulations containing them (see, for instance, W.J. Slichenmyer et al., Journal of the National Cancer Institute, Vol. 85, No. 4, 1993, pp 271-291 and, in particular, page 275 for 9-amino camptothecin).

Therefore, there is a need to find new camptothecin derivatives that, while maintaining or increasing
biological activity of camptothecin are, in the same time, endowed with water solubility and/or chemico-
physical characteristics which make these derivatives suitable for being included in pharmaceutically
acceptable formulations.
The compounds of this invention fulfill such a need.

Description of the invention
Accordingly, the present invention relates to camptothecin derivatives of formula (I)

wherein

B is a group B' or B''

wherein

each of (x) and (y) is a single or double bond,
R₁ and R₂ are each independently hydrogen, C₁−C₆ alkyl,
C₃-C₇ cycloalkyl, phenyl C₁-C₆ alkyl or an unsubstituted or substituted phenyl ring,

R₃ and R₄ are

(a) each independently substituents having the same meaning of R₁ and R₂ or

(b) combined together with the nitrogen atom to which they are linked to form a 3-7 membered saturated, unsubstituted or substituted heteromonocyclic ring, which may additionally contain another heteroatom selected from nitrogen, oxygen and sulphur, and

A⁻ is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid, provided that

(i) when (x) is a double bond, (y) is a single bond and when (y) is a double bond, (x) is a single bond,

(ii) when B is a group B′, then one of R₂, R₃ and R₄ is absent;

R₆ is hydrogen or C₁-C₆ alkyl; and

X is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ acyloxy, C₁-C₇ cycloalkyl, C₃-C₇ cycloalkoxy, benzoyloxy, amino, hydroxy, nitro, a halogen atom or a methylenedioxy group linked to the positions 10 and 11 of the molecule.

The invention includes also the pharmaceutically acceptable salts of the compounds of formula (I).

In the formulae of the present specification, a dotted
line (.....) indicates a substituent in the α-configuration, i.e. below the plane of the ring; a wedged line ( \( \uparrow \) ) indicates a substituent in the β-configuration, i.e. above the plane of the ring.

In this specification, the hydrocarbon chain of the alkyl, alkoxy and acyloxy groups may be a straight or a branched chain.

Preferably, B is linked to the position 9 or 10 of the molecule.

Preferably, \( C_1-C_6 \) alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or t-butyl.

Preferably, \( C_1-C_7 \) cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

Preferably, phenyl \( C_1-C_6 \) alkyl is benzyl, phenyl-ethyl or phenyl-propyl.

Preferably, \( C_1-C_6 \) alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy or n-butoxy.

Preferably, \( C_3-C_7 \) cycloalkoxy is cyclopropoxy, cyclobutoxy, cyclopentyloxy or cyclohexyloxy.

Preferably, \( C_1-C_6 \) acyloxy is acetoxy, propanoyloxy or butanoyloxy.

A halogen atom is chlorine, bromine, fluorine or iodine, preferably chlorine or bromine.

When one of \( R_1, R_2, R_3 \) and \( R_4 \) is an unsubstituted or substituted phenyl ring, it may be represented by a group
wherein

Q is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ acyloxy or a halogen atom.

 preferably, Q is hydrogen; C₁-C₄ alkyl, in particular methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or sec-butyl; C₁-C₄ alkoxy, in particular methoxy, ethoxy or isopropoxy; or a halogen atom, in particular chlorine.

 Particularly preferred values of Q are hydrogen, methyl, ethyl, n-propyl, isopropyl, methoxy and chlorine.

 When R₃ and R₄ combined together with the nitrogen atom to which they are linked form a 3-7 membered saturated, substituted or unsubstituted heteromonocyclic ring, said ring may be represented by a group

\[
\begin{array}{c}
N \\
\bigcirc \\
\downarrow \\
(\text{CH}_2)^m \\
\end{array}
\]

wherein

Y is -O-, -S-, -CH₂- or >NR₅ wherein R₅ is hydrogen, C₁-C₆ alkyl, or a phenyl ring represented by the above group \(\text{Q}^0\), wherein Q is as defined above; and

m and n are each independently zero or an integer of 1 to 5, provided that, when one of m and n is zero, the other is not zero and that m+n is not greater than 5.

 Preferably, R₅ is hydrogen or methyl.
Preferably, R₃ and R₄ combined together with the nitrogen atom to which they are linked form aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneimine, piperazine, methylpiperazine or morpholine, in particular pyrrolidine, piperidine, hexamethyleneimine, piperazine, methylpiperazine or morpholine.

A⁻ is a pharmaceutically acceptable anion of pharmaceutically acceptable acids, both inorganic acids such as, e.g., hydrochloric, sulfuric, phosphoric, di-, phosphoric, hydrobromic or nitric acid, and organic acids such as, e.g., citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, phenylacetic, methanesulfonic, ethanesulfonic, benzene-sulfonic or p-toluenesulfonic acid.

Preferably, A⁻ is a halide, acetate, benzoate, methanesulfonate, or p-toluenesulfonate anion, in particular chloride, acetate, methanesulfonate or p-toluenesulfonate anion.

Preferably, R₄ is hydrogen, methyl or ethyl.

Preferably, X is hydrogen, hydroxy, amino, nitro, a halogen atom, methoxy, acetoxy, propanoyloxy, benzoyloxy or 10,11 methylenedioxy, in particular hydrogen, hydroxy, methoxy or 10,11 methylenedioxy.

As already said, the present invention includes camptothecin derivatives of formula (I) in the form of free bases and in the form of pharmaceutically
acceptable salts with pharmaceutically acceptable acids both inorganic and organic acids.

Preferred salts according to the invention are the salts with pharmaceutically acceptable acids, both inorganic such as, e.g., hydrochloric, sulfuric, phosphoric, diphosphoric, hydrobromic or nitric acid, and organic acids such as, e.g., citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, phenylacetic, methanesulfonic, ethanesulfonic, benzenesulfonic or p-toluenesulfonic acid.

It is intended that also pharmaceutically acceptable quaternary ammonium salts, namely the compounds of formula (I) wherein B is a group B", are encompassed in the general definition "pharmaceutically acceptable salts" of the compounds of formula (I) of the present invention.

A preferred class of compounds according to the invention are the compounds of formula (I), wherein B is a group B' or B"

wherein each of (x) and (y) is a single or double bond,
R₁, R₂, R₃ and R₄ are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, cyclopentyl, cyclohexyl, benzy1, phenyl-ethyl or an unsubstituted or substituted phenyl ring represented by a group

wherein Q is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluorine, chlorine or bromine,
A⁻ is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid selected from chloride, acetate, methanesulfonate and p-toluene-sulfonate, provided that
(i) when (x) is a double bond, (y) is a single bond and when (y) is a double bond, (x) is a single bond, and
(ii) when B is a group B', then one of R₂, R₃ and R₄ is absent;
R₆ is hydrogen, methyl or ethyl;
X is hydrogen, hydroxy, methoxy or a methylenedioxy group linked to the positions 10 and 11 of the molecule; and the pharmaceutically acceptable salts thereof.
Another preferred class of compounds according to the invention are compounds of formula (I) wherein
B is a group B' or B"

wherein each of (x) and (y) is a single or double bond,

5 R₁ and R₂ are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, phenyl-ethyl, or an unsubstituted or substituted phenyl ring represented by a group

wherein Q is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluorine, chlorine or bromine,

15 R₃ and R₄ combined together with the nitrogen atom to which they are linked form pyrrolidine, piperidine, hexamethyleneimine, piperazine, methylpiperazine or morpholine.

A⁻ is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid, selected from chloride, acetate, methanesulfonate, and
p-toluenesulfonate, provided that

(i) when \((x)\) is a double bond, \((y)\) is a single bond and

when \((y)\) is a double bond, \((x)\) is a single bond,

and

(ii) when \(B\) is a group \(B'\), then one of \(R_2\), \(R_3\) and \(R_4\) is absent;

\(R_4\) is hydrogen, methyl or ethyl;

\(X\) is hydrogen, hydroxy, methoxy or a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof.

Examples of specific compounds preferred under the invention are the following:

(1) 9-(iminomethyl-amino)-camptothecin;

(2) 9-(1-imino-ethylamino)-camptothecin;

(3) 9-(methylimino-methylamino)-camptothecin;

(4) 9-(dimethylamino-methyleneamino)-camptothecin;

(5) 9-(dimethylamino-cyclohexyl-methyleneamino)-camptothecin;

(6) 9-[(imino-phenyl-methyl)-(amino)-camptothecin;

(7) 9-(1-phenylimino-ethylamino)-camptothecin;

(8) 9-(1-morpholin-4-yl-ethylideneamino)-camptothecin;

(9) 10-(iminomethyl-amino)-camptothecin;

(10) 10-(1-imino-ethylamino)-camptothecin;

(11) 10-(methylimino-methylamino)-camptothecin;

(12) 10-(dimethylamino-methyleneamino)-camptothecin;

(13) 10-(dimethylamino-cyclohexyl-methyleneamino)-
camptothecin;

10-{(imino-phenyl-methyl)-amino}-camptothecin;

10-(1-phenylimino-ethylamino)-camptothecin;

10-(1-morpholin-4-yl-ethylideneamino)-camptothecin;

10-hydroxy-9-{(imonomethyl-amino)-camptothecin;

10-hydroxy-9-{(1-imino-ethylamino)-camptothecin;

10-hydroxy-9-{(1-dimethylamino-ethylideneamino)-camptothecin;

11-hydroxy-9-{(21) iminomethyl-amino)-camptothecin;

11-hydroxy-9-{[(imino-phenyl-methyl)-amino]-camptothecin;

11-hydroxy-9-{(1-phenylimino-ethylamino)-camptothecin;

10-hydroxy-9-{(1-morpholin-4-yl-ethylideneamino)-camptothecin;

10,11-methylenedioxy-9-{(imonomethyl-amino)-camptothecin;

10,11-methylenedioxy-9-{(1-imino-ethylamino)-camptothecin;

10,11-methylenedioxy-9-{[(methylamino-methyl)-amino]-camptothecin;

10,11-methylenedioxy-9-{(1-imino-propylamino)-camptothecin;

10,11-methylenedioxy-9-{(1-methylamino-ethylamino)-camptothecin;

10,11-methylenedioxy-9-{[(ethyl-methyl-amino)-camptothecin;
- 12 -

methyleneamino]-camptothecin;

(30) 10,11-methylenedioxy-9-[(cyclohexyl-methylamino-methyl)-amino]-camptothecin;

(31) 9-[1-(4-methyl-piperazin-1-yl)-methyleneamino]-camptothecin;

(32) 10-methoxy-9-(iminomethyl-amino)-camptothecin;

(33) 10-methoxy-9-(1-imino-ethylamino)-camptothecin;

(34) 10-methoxy-9-(1-imino-pentylamino)-camptothecin;

(35) 10-methoxy-9-[[imino-(4-methoxy-phenyl)-methyl]-amino]-camptothecin;

(36) 10-methoxy-9-[(phenylimino-methyl)-amino]-camptothecin;

(37) 10-methoxy-9-(dimethylamino-methyleneamino)-camptothecin;

(38) 10-methoxy-9-(iminomethyl-methylamino)-camptothecin;

(39) 9-(2-methyl-1-imino-propylamino)-camptothecin;

(40) 10-methoxy-9-(2-methyl-1-methylamino-propylamino)-camptothecin;

(41) 10-hydroxy-9-(2,2-dimethyl-1-imino-propylamino)-camptothecin;

(42) 10-methoxy-9-(pyrrolidin-1-yl-methyleneamino)-camptothecin;

(43) 10,11-methylenedioxy-9-[(tert-butylamino-methyl)-amino]-camptothecin;

(44) 9-[(isopropylamino-methyl)-amino]-camptothecin;

and
(45) 7-ethyl-9-(iminomethyl-amino)-camptothecin.

The structural formula of the above listed compounds is illustrated in the following Table 1, with reference to formula (I)
Table 1

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>Position of group B</th>
<th>X</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
<th>R₄</th>
<th>R₅</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>9</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>(2)</td>
<td>9</td>
<td>H</td>
<td>-CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>(3)</td>
<td>9</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-CH₃</td>
<td>-</td>
</tr>
<tr>
<td>(4)</td>
<td>9</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>-CH₃</td>
<td>-CH₃</td>
<td>H</td>
</tr>
<tr>
<td>(5)</td>
<td>9</td>
<td>H</td>
<td>-Cy</td>
<td>-</td>
<td>-CH₃</td>
<td>-CH₃</td>
<td>H</td>
</tr>
<tr>
<td>(6)</td>
<td>9</td>
<td>H</td>
<td><img src="" alt="Cyclohexane" /></td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(7)</td>
<td>9</td>
<td>H</td>
<td>-CH₃</td>
<td>H</td>
<td><img src="" alt="Cyclohexane" /></td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(8)</td>
<td>9</td>
<td>H</td>
<td>-CH₃</td>
<td>-</td>
<td><img src="" alt="Oxirane" /></td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>(9)</td>
<td>10</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>(10)</td>
<td>10</td>
<td>H</td>
<td>-CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>(11)</td>
<td>10</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-CH₃</td>
<td>-</td>
</tr>
<tr>
<td>(12)</td>
<td>10</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>-CH₃</td>
<td>-CH₃</td>
<td>H</td>
</tr>
<tr>
<td>(13)</td>
<td>10</td>
<td>H</td>
<td>-Cy</td>
<td>-</td>
<td>-CH₃</td>
<td>-CH₃</td>
<td>H</td>
</tr>
</tbody>
</table>
### Table 1 (cont.)

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>Position of group B</th>
<th>X</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
<th>R₄</th>
<th>R₄</th>
</tr>
</thead>
<tbody>
<tr>
<td>(14)</td>
<td>10</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(15)</td>
<td>10</td>
<td>H</td>
<td>-CH₃</td>
<td>H</td>
<td>-</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(16)</td>
<td>10</td>
<td>H</td>
<td>-CH₃</td>
<td>-</td>
<td>-</td>
<td>N</td>
<td>O</td>
</tr>
<tr>
<td>(17)</td>
<td>9</td>
<td>10-OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(18)</td>
<td>9</td>
<td>10-OH</td>
<td>-CH₃</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(19)</td>
<td>9</td>
<td>10-OH</td>
<td>-CH₃</td>
<td>-</td>
<td>-CH₃</td>
<td>-CH₃</td>
<td>H</td>
</tr>
<tr>
<td>(20)</td>
<td>9</td>
<td>11-OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(21)</td>
<td>9</td>
<td>11-OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(22)</td>
<td>9</td>
<td>11-OH</td>
<td>-CH₃</td>
<td>H</td>
<td>-</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(23)</td>
<td>9</td>
<td>10-OH</td>
<td>H</td>
<td>-</td>
<td>-</td>
<td>N</td>
<td>O</td>
</tr>
<tr>
<td>(24)</td>
<td>9</td>
<td>10,11</td>
<td>O</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
</tr>
<tr>
<td>(25)</td>
<td>9</td>
<td>10,11</td>
<td>-CH₃</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(26)</td>
<td>9</td>
<td>10,11</td>
<td>O</td>
<td>H</td>
<td>H</td>
<td>-CH₃</td>
<td>-</td>
</tr>
<tr>
<td>COMPOUND</td>
<td>Position of group B</td>
<td>X</td>
<td>R&lt;sub&gt;1&lt;/sub&gt;</td>
<td>R&lt;sub&gt;2&lt;/sub&gt;</td>
<td>R&lt;sub&gt;3&lt;/sub&gt;</td>
<td>R&lt;sub&gt;4&lt;/sub&gt;</td>
<td>R&lt;sub&gt;5&lt;/sub&gt;</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------</td>
<td>-------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>(27)</td>
<td>9</td>
<td>10,11</td>
<td>Et</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(28)</td>
<td>9</td>
<td>10,11</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(29)</td>
<td>9</td>
<td>10,11</td>
<td>H</td>
<td>-</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>Et</td>
<td>H</td>
</tr>
<tr>
<td>(30)</td>
<td>9</td>
<td>10,11</td>
<td>Cy</td>
<td>H</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(31)</td>
<td>9</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>-N</td>
<td>N-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
</tr>
<tr>
<td>(32)</td>
<td>9</td>
<td>10-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(33)</td>
<td>9</td>
<td>10-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(34)</td>
<td>9</td>
<td>10-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>n-Bu</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(35)</td>
<td>9</td>
<td>10-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(36)</td>
<td>9</td>
<td>10-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(37)</td>
<td>9</td>
<td>10-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>-</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
</tr>
<tr>
<td>(38)</td>
<td>9</td>
<td>10-OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(39)</td>
<td>9</td>
<td>H</td>
<td>i-Pr</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
</tbody>
</table>
Table 1 (cont.)

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>Position of group B</th>
<th>X</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
<th>R₄</th>
<th>R₅</th>
</tr>
</thead>
<tbody>
<tr>
<td>(40)</td>
<td>9</td>
<td>10-OCH₃</td>
<td>i-Pr</td>
<td>H</td>
<td>-CH₃</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(41)</td>
<td>9</td>
<td>10-OH</td>
<td>t-Bu</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(42)</td>
<td>9</td>
<td>10-OCH₃</td>
<td>H</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>H</td>
</tr>
<tr>
<td>(43)</td>
<td>9</td>
<td>10,11</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>t-Bu</td>
<td>-</td>
</tr>
<tr>
<td>(44)</td>
<td>9</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>i-Pr</td>
<td>-</td>
</tr>
<tr>
<td>(45)</td>
<td>9</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>-</td>
<td>Et</td>
</tr>
</tbody>
</table>

In Table 1, the symbols Et, i-Pr, n-Bu, t-Bu and Cy stand respectively for ethyl, isopropyl, n-butyl, t-butyl and cyclohexyl.

The compounds 1 to 45, listed on the above Table 1, may be also in the form of pharmaceutically acceptable salts.

The compounds of the present invention may be prepared by a process which comprises:

1) reacting a compound of formula (II)

![Diagram](image-url)
wherein R₂, R₆ and X are as defined above,

with a compound of formula (III)

\[
\begin{array}{c}
\text{III) }
\end{array}
\]

wherein R₁, R₃ and R₄ are as defined above, A⁻ is either a pharmaceutically acceptable anion A⁻ as defined above or any other suitable anion, and Z is a leaving group, so obtaining a compound of formula (I) wherein R₆ and X are as defined above, and wherein, according to the reaction conditions, B is a group B' or B" as defined above; and, if desired,

2) converting a compound of formula (I) wherein R₆ and X are as defined above, B is a group B" as defined above wherein one of R₃, R₃ and R₄ is hydrogen, into a corresponding compound of formula (I) wherein R₆ and X are as defined above and B is a group B' as defined above, and, if desired,

3) salifying a compound of formula (I) wherein R₆ and X are as defined above and B is a group B' as defined above, so obtaining a compound of formula (I) in the form of a pharmaceutically acceptable salt.

The starting compounds of formula (II) have a 20(S)-configuration which is retained throughout the process.
leading to the compounds of formula (I).

The compounds of formula (II) are typically free of the corresponding 20(R)-isomers.

However, said process may be applied to a racemic mixture of a compound of formula (II) and the corresponding 20(R)-isomer. In that case, a racemic mixture of a compound of formula (I) and a 20(R)-isomer of a compound of formula (I) is obtained.

In the compounds of formula (III), the leaving group Z may be C₁-C₄ alkoxy, C₅-C₁₀ cycloalkoxy, C₅-C₆ acyloxy, benzyloxy, C₅-C₁₀ cycloacyloxy, a halogen atom, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or methanesulfonyloxy.

Preferred meanings which Z may assume include methoxy, ethoxy, propoxy, isopropoxy, acetoxy, propanoyloxy, benzoyloxy, fluorine, chlorine, bromine, iodine, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or methanesulfonyloxy.

Particularly preferred meanings which Z may assume include methoxy, ethoxy, propoxy, isopropoxy, acetoxy, propanoyloxy, benzoyloxy, chlorine, bromine, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or methanesulfonyloxy.

In the compound of formula (III) A₁ is preferably a pharmaceutically acceptable anion A⁻ as defined above.

The reaction reported under the above item 1) may be
performed reacting a compound of formula (II) dissolved in a suitable solvent with from a stoichiometric quantity to a large excess of a compound of formula (III), at a temperature of from about -20°C to about 100°C, preferably from about 0°C to about 80°C, for a time which may vary from about few minutes to several days such as from 5 minutes to 3 days, preferably from about one hour to about one day, optionally in the presence of a suitable inorganic or organic base.

When the reaction of item 1) is carried out in the absence of a suitable inorganic or organic base, a compound of formula (I) wherein R₆ and X are defined above and wherein B is a group B' as defined above may be obtained. When the reaction of item 1) is carried out in the presence of a suitable inorganic or organic base, a compound of formula (I) wherein R₆ and X are as defined above and wherein B is a group B' as defined above may be obtained.

Suitable solvents include dimethylformamide (DMF), water, CH₃OH, acetic acid, CHCl₃, dioxane, tetrahydrofuran (THF) and mixtures thereof.

Suitable inorganic bases may be, for example, salts with alkali or alkaline earth metals, such as, for example, NaOH, NaHCO₃, Na₂CO₃ or CaCO₃.

Suitable organic bases may be, for example, trialkylamines such as, e.g., triethylamine or diisopropylethyl-
amine; or heteroaromatic bases such as, e.g., pyridine or 2,6-C$_1$-C$_6$ alkyl substituted pyridines such as, e.g., 2,6-lutidine.

The conversion reported under the above item 2) may be carried out following conventional procedures; for example, the conversion may be carried out in a suitable aqueous solvent by adding from a stoichiometric amount to a slight excess of an organic or inorganic base.

The organic or inorganic base which can be used under item 2) may be, for example, selected among those optionally used under item 1).

Conventional methods may be used in order to salify a compound of formula (I) as reported under item 3).

In particular, a compound of formula (I) wherein B is a group B' or B" linked to the position 9 of the molecule wherein R$_1$, R$_3$, R$_4$, (x), (y) and A' are as defined above and R$_5$ is hydrogen, and wherein R$_6$ is as defined above and X is 10- or 12-hydroxy, may be prepared reacting in situ, a corresponding compound of formula (II) wherein R$_6$ is as defined above, R$_1$ is hydrogen and X is 10- or 12-hydroxy, with a compound of formula (III) as defined above, without isolating said compound of formula (II) from the reaction mixture in which it has been obtained, by reduction of a compound of formula (IV)

![Chemical Structure](image-url)
wherein $R_6$ is as defined above and the hydroxy group is linked to the position 10 or 12 of the molecule. The reduction of the compound of formula (IV) may be carried out, for example, with suitable reducing agents, or by catalytic reduction with suitable catalysts, in the presence of suitable reducing agents. For example, it may be performed as described in: J. March, Advanced Organic Chemistry, Third Edition, 1103. For instance, the reduction may be performed with reducing agents such as, SnCl₂, or other metals or metal salts, such as Zn or Fe and their salts, in a suitable solvent such as dilute aqueous HCl, dilute aqueous protic acids, water, ethanol, methanol, or mixtures thereof, at a temperature of from −20°C to 60°C, for a period of from few minutes to several days such as from 5 minutes to 3 days, for example from 4 hours to 24 hours; or by the use of catalytic amounts of metals which perform nitro group reduction, such as, palladium, platinum oxide, platinum, Pd L₂ wherein L is acetate or a halogen atom, rhodium or ruthenium, in the presence of molecular hydrogen or hydrogen sources, such as triethylammonium formate, formic acid, tributyltin hydride, cyclohexadiene, polymethylhydrosiloxane, etc., in a suitable solvent, such as dimethylformamide (DMF), CH₂OH, acetic acid, CHCl₃, dioxane, or mixtures thereof, at a temperature of from about 0°C to 100°C, for a time of from 1 hour to 3
days, and at a pressure of from 1 atm to 100 atm.
The compounds of formula (II) and (III) are known compounds or may be obtained following known methods.
The compounds of formula (IV) may be obtained, for example, reacting a 10-hydroxy or 12-hydroxy camptothecin with suitable common nitrating agents such as, e.g., nitric acid, mixtures of nitric and sulphuric acid, or other nitrating agents such as, e.g., potassium nitrate or nitric acid and boron trifluoride such as boron trifluoride monohydrate (see for instance Olah, G.A. et al., Synthesis 1085, 1992), or nitric acid/trifluoromethanesulfonylic anhydride (ibid., 1087, 1992), at a temperature of from -20°C to 100°C, for a time of from a few minutes to several days such as from 5 minutes to 3 days, for example from 4 hours to 24 hours.
In particular, 10-hydroxy-camptothecin is a natural product found in the same plant as camptothecin (see for instance Wani et al., J. Org. Chem., 34, 1364, 1969).
The compounds of formula (I) are water soluble by the virtue of the basic side chain represented by the basic group B which may form salts with pharmaceutically
acceptable inorganic or organic acids. The solubility of the compounds of formula (I) in water is especially important since it permits the administration of these compounds in aqueous pharmaceutical compositions.

The compounds of the present invention are endowed with antitumor activity, for example they are effective against leukemia and solid tumors such as, for example, colon and rectal tumors.

The antitumor activity of the compounds of the present invention was shown, for example, by the fact that they have been found to possess both "in vitro" cytotoxic activity and "in vivo" antileukemic activity.

As an example, the activity of 9-(iminomethyl-amino)-camptothecin (internal code FCE 28536) and 9-(dimethylamino-methyleneamino)-camptothecin (internal code FCE 29006) were tested according to the following methods (a) and (b).

Method (a): evaluation of cytotoxic activity

L1210 murine leukemia cells were grown in vitro as a stationary suspension in RPMI 1640 medium supplemented with 10% fetal calf serum, 2mM L-glutamine, 10μM B-mercaptoethanol, 100 UI/ml penicillin and 100 μg streptomycin. For assaying the cytotoxic activity, exponentially growing cells were seeded at the concentration of 1x10^5 cells/ml and exposed to graded doses of the compounds under evaluation for 48h at 37°C in an humidified atmosphere of 5% CO₂. The number of
surviving cells was determined with a Coulter Counter; results are expressed as IC50 (dose causing 50% inhibition of cell growth in treated cultures relative to untreated controls after 48h treatment).

In this assay, 9-(iminomethyl-amino)-camptothecin (internal code FCE 28536) and 9-(dimethylamino-methyleneamino)-camptothecin (internal code FCE 29006) were tested and the obtained results, which represent the mean of 3 different experiments, are reported on Table 1 below.

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCE 28536</td>
<td>82</td>
</tr>
<tr>
<td>FCE 29006</td>
<td>120</td>
</tr>
</tbody>
</table>

Method (b): evaluation of antitumor activity

L1210 murine leukemia was maintained in DBA2 mice by weekly ip transplants of 105 cells/mouse. For assaying the antileukemic activity, 105 cells/mouse were implanted ip into CD2F1 mice; graded doses of the compounds under evaluation were administered ip 24 h after tumor cells implant on day 1 controls receiving vehicle alone.

The activity of the drugs was determined evaluating the median survival time (MST) of each group of mice.
The obtained results, expressed as % T/C, are reported on Table 2 below.

Table 2

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>DOSE (mg/kg)</th>
<th>%T/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>28536</td>
<td>5</td>
<td>150-163</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>188</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>219-213</td>
</tr>
<tr>
<td>29006</td>
<td>5</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>163</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>175</td>
</tr>
</tbody>
</table>

%TC = MST treated mice/MST control mice X100

A human or animal body may thus be treated by a method which comprises the administration thereto of a pharmaceutically effective amount of a compound of formula (I) or salt thereof. The condition of the human or animal can thereby be improved.

The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, lozengers, liquid solutions or suspensions; rectally, in the form of suppositories;
parenterally, e.g. intramuscularly, intravenously, intradermally or subcutaneously; or topically.

The dosage depends upon, for example, the camptothecin derivative employed, the potency of the camptothecin derivative, the age, weight, condition of the patient and administration route; specific dosage regimens may be fit to any particular subject on the basis of the individual need and the professional judgement of the person administering or supervising the administration of the aforesaid compounds. For example, the dosage adopted for the administration to adult humans may range from 0.1 to 60 mg of camptothecin derivative per kg of body weight; a particularly preferred range may be from 1 to 40 mg of camptothecin derivative per kg of body weight.

The dosages may be administered at once or may be divided into a number of smaller doses to be administered at varying intervals of time. Pharmaceutical compositions containing as an active ingredient a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier and/or diluent are also within the scope of the present invention. These pharmaceutical compositions contain an amount of active ingredient which is therapeutically effective to display antileukemic and/or antitumor activity. There may also be included as a part of the pharma-
ceutical compositions according to the invention, pharmaceutically acceptable binding agents and/or adjuvant materials. The active ingredients may also be mixed with other active principles which do not impair the desired action and/or supplement the desired action. The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and may be administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, microcrystalline cellulose, carboxymethylcellulose or polyvinyl pyrrolidone; diaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweetening agents, e.g. sucrose or saccharin; flavouring agents, e.g. peppermint, methyl-salicylate or orange flavouring; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.

When the dosage unit form is a capsule, it may contain, in addition to material of the above type, a liquid
carrier such as, e.g., a fatty oil.

Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating or film-coating processes. The liquid dispersions for oral administration may be, e.g. syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol; in particular, a syrup to be administered to diabetic patients can contain as carriers only products not metabolizable to glucose, or metabolizable in very small amount to glucose, for example sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.

The solutions for intravenous injections or infusions may contain as carrier, for example, sterile water, or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
The solutions or suspensions for parenteral therapeutic administration may also contain antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulphite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g., coca-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

Compositions for topical application, such as, e.g., creams, lotions or pastes, may be, e.g., prepared by admixing the active ingredient with a conventional oleaginous or emulsifying excipient.

The following examples illustrate but do not limit the invention.

The number into bracket reported after the chemical name of the compounds prepared according to the following examples corresponds to the number given to the preferred compounds listed on pages 11, 12 and 13 of the present specification.

Example 1

9-(iminomethyl-amino)-camptothecin (1).
To a stirred solution of 9-amino camptothecin (0.5 g) in DMF (100 ml), ethyl formimidate hydrochloride (2.5 g) was added at room temperature, and the resulting mixture was stirred overnight. The solid was filtered off and the filtrate was evaporated in vacuo. The residue was taken-up with water and the pH of the resulting solution was adjusted to about 6.5. The precipitated solid was collected by filtration, carefully washed with small portions of cold water, and then dried to yield the title product (0.25 g).

$^1$NMR(DMSO-$d_6$), δ ppm: 0.87 (3H, t, J=7.3 Hz); 1.85 (2H, m); 5.27 (2H, s); 5.41 (2H, s); 6.50 (1H, broad signal); 7.04 (1H, d, J=7.3 Hz); 7.10 (2H, broad signal); 7.31 (1H, s); 7.67 (1H, dd, J=7.3, 8.5 Hz); 7.73 (1H, d, J=8.5 Hz); 7.79 (1H, m); 8.94 (1H, s). MS (FD): 390.

The title product (0.1 g) was suspended in water (2 ml) and 1N HCl (0.3 ml) was added. The resulting yellow solution was then freeze dries to yield the hydrochloride salt of the title product.

Following analogous procedure the below listed compounds and their hydrochloride salts can be prepared:

10,11-methylenedioxy-9-(iminomethyl-amino)-camptothecin (24);

10-methoxy-9-(iminomethyl-amino)-camptothecin (32);

10-(iminomethyl-amino)-camptothecin (9);

11-hydroxy-9-(iminomethyl-amino)-camptothecin (20); and

7-ethyl-9-(iminomethyl-amino)-camptothecin (45).
Example 2

10-hydroxy-9-(iminomethyl-amino)-camptothecin (17).

A solution of 10-hydroxy-9-nitro camptothecin (0.5 g) in DMF (100 ml) was hydrogenated at atmospheric pressure and room temperature in the presence of 10% Pd/C (0.05 g) until H₂ consumption ceased. The resulting solution was filtered and then treated with ethyl formimidate hydrochloride (1.5 g). The solution was stirred overnight and worked-up as described in Example 1, to yield the title compound (0.1 g).

Example 3

9-(1-imino-ethylamino)-camptothecin (2).

To a stirred solution of 9-amino camptothecin (0.5 g) in DMF (100 ml), ethyl acetamidate hydrochloride (2.5 g) was added and the resulting mixture was stirred at 80°C overnight and worked-up as described in Example 1, to yield the title compound (0.2 g).

Following analogous procedure the below listed compounds and their hydrochloride salts can be prepared:

20 10,11-methyleneedioxyoxy-9-(1-imino-ethylamino)-camptothecin (25);
10-methoxy-9-(1-imino-methylamino)-camptothecin (38);
10-methoxy-9-(1-imino-ethylamino)-camptothecin (33);
10-(1-imino-ethylamino)-camptothecin (10);

25 9-[(imino-phenyl-methyl)-amino]-camptothecin (6);
10-[(imino-phenyl-methyl)-amino]-camptothetin (14);
11-hydroxy-9-[(imino-phenyl-methyl)-amino]-camptothecin (21);
10,11-methylenedioxy-9-(1-imino-propylamino)-camptothecin (27);
10-methoxy-9-(1-imino-pentylamino)-camptothecin (34);
10-methoxy-9-[(imino-(4-methoxy-phenyl)-methyl)-amino]-
camptothecin (35); and
9-(2-methyl-1-imino-propylamino)-camptothecin (39).

Example 4

10-hydroxy-9-(1-imino-ethylamino)-camptothecin (18).
A solution of 10-hydroxy-9-nitro camptothecin (0.5 g) in
DMF (100 ml) was hydrogenated at atmospheric pressure
and room temperature in the presence of 10% Pd/C (0.1 g)
until H₂ consumption ceased. The resulting solution was
treated with ethyl acetamidate hydrochloride (2.0 g),
and left at room temperature overnight. The solution was
worked-up as described in previous examples, to yield
the title compound (0.2 g).

Following analogous procedure the below listed compounds
can be obtained:
10-hydroxy-9-(2,2-dimethyl-1-imino-propylamino)-
camptothecin (41);
10-hydroxy-9-(1-dimethylamino-ethylideneamino)-
camptothecin (19); and
10-hydroxy-9-(1-morpholin-4-yl-ethylideneamino)-
camptothecin (23).
Example 5
By analogy with the previous Example 1 by using the appropriate imidate, the following compounds can be prepared:

5 9-[(methylimino-methyloamino)-camptothecin (3);
9-[(dimethyloamino-methylenearino)-camptothecin (4);
9-[(dimethyloamino-cyclohexyl-methylenearino)-camptothecin (5);
9-[(1-phenyloimino-ethylamino)-camptothecin (7);
10 9-[(1-morpholin-4-yl-ethylideneamino)-camptothecin (8);
10-[(methyloimino-methyloamino)-camptothecin (11);
10-[(dimethyloamino-methylenearino)-camptothecin (12);
10-[(dimethyloamino-cyclohexyl-methylenearino)-camptothecin (13);
15 10-[(1-phenyloimino-ethylamino)-camptothecin (15);
10-[(1-morpholin-4-yl-ethylideneamino)-camptothecin(16);
11-hydroxy-9-[(1-phenyloimino-ethylamino)-camptothecin (22);
10,11-methyleneedioxy-9-[(methyloimino-methyl)-amino]-camptothecin (26);
10,11-methyleneedioxy-9-[(1-methyloimino-ethylamino)-camptothecin (28);
10,11-methyleneedioxy-9-[(ethyl-methyl-amino)-methylenearino]-camptothecin (29);
25 10,11-methyleneedioxy-9-[(cyclohexyl-methyloimino-methyl)-
amino]-camptothecin (30);
9-[(1-(4-methyl-piperazin-1-yl)-methylenearino]-
camptothecin (31);
10-methoxy-9-[(phenylimino-methyl)-amino]-camptothecin (36);
10-methoxy-9-(dimethylamino-methyleneamino)-camptothecin (37);
10-methoxy-9-(2-methyl-1-methylimino-propylamino)-camptothecin (40);
10-methoxy-9-(pyrrolidin-1-yl-methyleneamino)-camptothecin (42);
10,11-methylenedioxy-9-[(tert-butylimino-methyl)-amino]-camptothecin (43); and
9-[(isopropylimino-methyl)-amino]-camptothecin (44).

Example 6
9-(dimethylamino-methyleneamino)-camptothecin (4)

Oxalyl chloride (1.15 ml) in ether (5 ml) was added at -40°C to a stirred solution of dimethylformamide (1 ml) in ether (50 ml).

The mixture was then stirred at room temperature for three hours. The precipitate was filtered, washed with ether, and added at room temperature to a solution of 9-amino camptothecin (150 mg) in DMF (20 ml).

The mixture was stirred at room temperature overnight. The reaction mixture was then evaporated "in vacuo", and the residue was taken up with water. The aqueous solution was then washed twice with CH₂Cl₂ and the organic layer was discharged. The pH of the aqueous
layer was then adjusted by addition of NaHCO₃, till complete precipitation of a yellow-brown solid was observed. The solid was collected by filtration and carefully washed with water. The crude product was then purified with reverse phase chromatography eluting with acidic-water/acetone mixtures. The appropriate fractions were collected, and freeze dried.
The residue was taken-up with water (3 ml), and NaHCO₃ was added until a complete precipitation was observed. The precipitate was collected by filtration, carefully washed with water, and dried, to yield the title product (90 mg).

NMR (DMSO-d₆) δ (ppm): 0.87 (3H, T, J = 7.3 Hz); 1.85 (2H, m); 3.10 (6H, s); 5.27 (2H, s); 5.41 (2H, s); 6.50 (1H, s); 7.08 (1H, m); 7.31 (1H, s); 7.68 (2H, m); 7.94 (1H, s); 9.04 (1H, s).

MS (PD): 418

The above precipitate (80 mg) was suspended again in water (2 ml) and 1N HCl (0.2 ml) was added. The solution was then freeze-dried to afford the title product as hydrochloride salt.

**Example 7**

9-(1-imino-ethylamino)-camptothecin (2)
The reaction was performed as described in Example 3, but using dimethylacetamide.
After usual work-up there were obtained 0.1 g of the title product.
CLAIMS

1. A camptothecin derivative of formula (I)

\[ 
\text{wherein}
\]

\[ 
B \text{ is a group } B' \text{ or } B''
\]

\[ 
\text{wherein}
\]

each of \((x)\) and \((y)\) is a single or double bond;

\(R_1\) and \(R_2\) are each independently hydrogen, \(C_1-C_6\) alkyl,

\(C_3-C_7\) cycloalkyl, phenyl \(C_1-C_5\) alkyl or an unsubstituted or substituted phenyl ring,

\(R_3\) and \(R_4\) are

(a) each, independently, substituents having the same meaning of \(R_1\) and \(R_2\) or

(b) combined together with the nitrogen atom to
which they are linked to form a 3-7 membered saturated, unsubstituted or substituted heteromonocyclic ring, which may additionally contain another heteroatom selected from nitrogen, oxygen and sulphur, and A is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid, provided that

(i) when (x) is a double bond, (y) is a single bond and when (y) is a double bond, (x) is a single bond, and

(ii) when B is a group B', then one of R₂, R₃ and R₄ is absent;

R₅ is hydrogen or C₁-C₆ alkyl;

X is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ acyloxy, C₁-C₇ cycloalkyl, C₅-C₇ cycloalkoxy, benzoyloxy, amino, hydroxy, nitro, a halogen atom or a methylenedioxy group linked to the position 10 and 11 of the molecule; or a pharmaceutically acceptable salt thereof.

2. A camptothecin derivative of formula (I) according to claim 1, wherein B is a group B' or B''
wherein
each of (x) and (y) is a single or double bond;
R₁, R₂, R₃ and R₄ are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, phenyl-ethyl or an unsubstituted or substituted phenyl ring represented by a group

wherein Q is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, methoxy, ethoxy, n-propoxy, isoproxy, fluorine, chlorine or bromine,
A is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid selected from chloride, acetate, methanesulfonate and p-toluenesulfonate, provided that
(i) when (x) is a double bond, (y) is a single bond and when (y) is a double bond, (x) is a single bond, and
(ii) when B is a group B', then one of R₂, R₃ and R₄ is absent;
R₄ is hydrogen, methyl or ethyl;
X is hydrogen, hydroxy, methoxy or a methylenedioxy group linked to the positions 10 and 11 of the
molecule; or a pharmaceutically acceptable salt thereof.

3. A camptothecin derivative of formula (I) according to claim 1, wherein B is a group B' or B"

![Chemical Structure](image)

wherein

each of (x) and (y) is a single or double bond,

R₁ and R₂ are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, phenyl-ethyl, or an unsubstituted or substituted phenyl ring represented by a group

![Phenyl Ring](image)

wherein Q is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluorine, chlorine or bromine,

R₃ and R₄ combined together with the nitrogen atom to which they are linked form pyrrolidine, piperidine,
hexamethylenimine, piperazine, methylpiperazine or morpholine,
A is a pharmaceutically acceptable anion of a pharmaceutically acceptable inorganic or organic acid, selected from chloride, acetate methane-sulfonate and p-toluenesulfonate, provided that
5 (i) when (x) is a double bond, (y) is a single bond and when (y) is a double bond, (x) is a single bond, and
(ii) when B is a group B', then one of R₂, R₃ and R₄ is absent;
10 R₄ is hydrogen, methyl or ethyl;
X is hydrogen, hydroxy, methoxy or a methylenedioxy group linked to the position 10 and 11 of the molecule; or a pharmaceutically acceptable salt thereof.

4. A camptothecin derivative selected from:
   (1) 9-(iminomethyl-amino)-camptothecin;
   (2) 9-(1-imino-ethylamino)-camptothecin;
   (3) 9-(methylimino-methylamino)-camptothecin;
   (4) 9-(dimethylamino-methyleamino)-camptothecin;
   (5) 9-(dimethylamino-cyclopentenyl-methyleamino)-camptothecin;
   (6) 9-[(iminophenyl-methyl)-amino]-camptothecin;
   (7) 9-(1-phenylimino-ethylamino)-camptothecin;
9-[(1-morpholin-4-yl-ethylideneamino)-camptothecin;
10-[(iminomethyl-ethylamino)-camptothecin;
10-[(1-imino-ethylamino)-camptothecin;
10-[(methylimino-methylamino)-camptothecin;
10-[(dimethylamino-methyleneamino)-camptothecin;
10-[(dimethylamino-cyclohexyl-methyleneamino)-camptothecin;
10-[(imino-phenyl-methyl)-amino]-camptothecin;
10-[(1-phenylimino-ethylamino)-camptothecin;
10-[(1-morpholin-4-yl-ethylideneamino)-camptothecin;
10-hydroxy-9-[(iminomethyl-ethylamino)-camptothecin;
10-hydroxy-9-[(1-imino-ethylamino)-camptothecin;
10-hydroxy-9-[(dimethylamino-ethylideneamino)-camptothecin;
11-hydroxy-9-[(iminomethyl-ethylamino)-camptothecin;
11-hydroxy-9-[(imino-phenyl-methyl)-amino]-camptothecin;
11-hydroxy-9-[(1-phenylimino-ethylamino)-camptothecin;
10-hydroxy-9-[(1-morpholin-4-yl-ethylideneamino)-camptothecin;
10,11-methylenedioxy-9-[(iminomethyl-ethylamino)-camptothecin;
10,11-methylenedioxy-9-(1-imino-ethylamino)-camptothecin;

10,11-methylenedioxy-9-[(methylimino-methyl)-amino]-camptothecin;

10,11-methylenedioxy-9-(1-imino-propylamino)-camptothecin;

10,11-methylenedioxy-9-(1-methylimino-ethylamino)-camptothecin;

10,11-methylenedioxy-9-[(ethyl-methyl-amino)-methyleneamino]-camptothecin;

10,11-methylenedioxy-9-[(cyclohexyl-methylimino-methyl)-amino]-camptothecin;

9-{1-(4-methyl-piperazin-1-yl)-methylene-amino}-camptothecin;

10-methoxy-9-(iminomethyl-amino)-camptothecin;

10-methoxy-9-(1-imino-ethylamino)-camptothecin;

10-methoxy-9-(1-imino-pentylamino)-camptothecin;

10-methoxy-9-[(imino-(4-methoxy-phenyl)-methyl)-amino]-camptothecin;

10-methoxy-9-[(phenylimino-methyl)-amino]-camptothecin;

10-methoxy-9-(dimethylamino-methyleneamino)-camptothecin;

10-methoxy-9-(iminomethyl-methylamino)-camptothecin;
(39) 9-(2-methyl-1-imino-propylamino)-camptothecin;

(40) 10-methoxy-9-(2-methyl-1-methylamino-propylamino)-camptothecin;

(41) 10-hydroxy-9-(2,2-dimethyl-1-imino-propylamino)-camptothecin;

(42) 10-methoxy-9-(pyrrolidin-1-yl-methyleneamino)-camptothecin;

(43) 10,11-methylenedioxy-9-[(tert-butyloximino-methyl)-amino]-camptothecin;

(44) 9-[(isopropylimino-methyl)-amino]-camptothecin;

(45) 7-ethyl-9-(iminomethyl-amino)-camptothecin, and their pharmaceutically acceptable salts.

5. A process for the preparation of a camptothecin derivative of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, the process comprising

1) reacting a compound of formula (II)

![Chemical Structure](image)

(II)

wherein R₂, R₆ and X are as defined in claim 1, with a compound of formula (III)

![Chemical Structure](image)

(III)
wherein \( R_1, R_3, \) and \( R_4 \) are as defined in claim 1, \( A_1 \) is either a pharmaceutically acceptable anion \( A' \) as defined above or any other suitable anion and \( Z \) is a leaving group, so obtaining a compound of formula (I) wherein \( R_6 \) and \( X \) are as defined in claim 1, and wherein, according to the reaction conditions, \( B \) is a group \( B' \) or \( B'' \) as defined in claim 1 and, if desired,

2) converting a compound of formula (I) wherein \( R_6 \) and \( X \) are as defined in claim 1, \( B \) is a group \( B'' \) as defined in claim 1 and wherein one of \( R_2, R_3, \) and \( R_4 \) is hydrogen, into a corresponding compound of formula (I) wherein \( R_6 \) and \( X \) are as defined in claim 1 and \( B \) is a group \( B' \) as defined in claim 1, and, if desired,

3) salifying a compound of formula (I) wherein \( R_6 \) and \( X \) are as defined in claim 1 and \( B \) is a group \( B' \) as defined in claim 1.

6. A pharmaceutical composition comprising a camptothecin derivative of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1 as an active principle, and a pharmaceutically acceptable carrier and/or diluent.
7. A camptothecin derivative of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use in a method of treatment of the human or animal body by therapy.

8. A compound as claimed in claim 7 for use as an antitumor agent.

9. Use of a compound of formula (I) or a pharmaceutically salt thereof, as defined in claim 1, in the preparation of a pharmaceutical composition for use as an antitumor agent.
# INTERNATIONAL SEARCH REPORT

**PCT/EP 95/00393**

### A. CLASSIFICATION OF SUBJECT MATTER

**IPC** 6 C07D491/22 A61K31/47 // (C07D491/22, 311:00, 221:00, 221:00, 209:00), (C07D491/22, 317:00, 311:00, 221:00, 221:00, 209:00)

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

**IPC** 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>EP-A-0 321 122 (SMITHKLINE BECKMAN CORPORATION) 21 June 1989 see the whole document</td>
<td>1-9</td>
</tr>
</tbody>
</table>

* Further documents are listed in the continuation of box C.

**X** Patent family members are listed in annex.

* Special categories of cited documents:
  - 'A' document defining the general state of the art which is not considered to be of particular relevance
  - 'E' earlier document but published on or after the international filing date
  - 'L' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - 'O' document referring to an oral disclosure, use, exhibition or other means

<table>
<thead>
<tr>
<th>Date of the actual completion of the international search</th>
<th>Date of mailing of the international search report</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 June 1995</td>
<td>26.07.95</td>
</tr>
</tbody>
</table>

* Name and mailing address of the ISA
  European Patent Office, P.B. 5818 Patentlaan 2
  NL - 2280 HV Rijswijk
  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
  FAX (+31-70) 340-3016

* Authorized officer
  Hartrampf, G

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 3
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>EP-A-0 418 099 (RESEARCH TRIANGLE INSTITUTE) 20 March 1991 see page 8, line 20 - page 10, line 30</td>
<td>1-9</td>
</tr>
<tr>
<td>Y</td>
<td>WO-A-91 04260 (RESEARCH TRIANGLE INSTITUTE) 4 April 1991 see page 13, line 25 - page 19, line 6</td>
<td>1-9</td>
</tr>
<tr>
<td>Y</td>
<td>WO-A-92 05785 (SMITHKLINE BEECHAM CORPORATION) 16 April 1992 see the whole document</td>
<td>1-9</td>
</tr>
<tr>
<td>A</td>
<td>CANCER RESEARCH, vol. 49, no. 6, 15 March 1989 pages 1465-1469, JAXEL C. ET AL. 'Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity' cited in the application see the whole document</td>
<td>1,6-9</td>
</tr>
<tr>
<td>A</td>
<td>CANCER RESEARCH, vol. 49, no. 16, 15 August 1989 pages 4385-4389, HSIANG Y.-H. ET AL. 'DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues' cited in the application see the whole document</td>
<td>1,6-9</td>
</tr>
</tbody>
</table>

Form PCT/ISA/218 (continuation of second sheet) (July 1992)
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN-B- 1027265</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN-A- 1087637</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN-A- 1083817</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-A- 88517</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-B- 6033268</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT-B- 89111</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 5004758</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-B- 6015547</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 1332414</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-T- 68906552</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES-T- 2056962</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 5061800</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 5180722</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2066780</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-T- 5502017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-B- 640950</td>
</tr>
<tr>
<td>WO-A-9104260</td>
<td>04-04-91</td>
<td>AU-B- 640950</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2090967</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN-A- 1062731</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ-A- 9300515</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-T- 6501476</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ-A- 239947</td>
</tr>
</tbody>
</table>